whitepaper
Application note: Validation of identified through AI
Targets for drug discovery can be identified with AI but require validation in vitro. Here’s how this can be done, using hiPSC technology.
List view / Grid view
Ncardia
whitepaper
Case study: Parkinson’s disease modelling for drug discovery
The development of a Parkinson’s disease model, using hiPSC-derived neural cells, to assess alpha-synuclein pre-formed fibril-induced toxicity.
whitepaper
Whitepaper: Automated cell culture and screening
This whitepaper describes the automated culturing of hiPSC-derived cells for high-throughput phenotypic screening, using validated phenotypic assays.
whitepaper
Interview: Stefan Braam, CEO & Founder of Ncardia
Mass production with iPSCs: how Ncardia has pushed the boundaries with high-throughput iPSC research.
whitepaper
Whitepaper: Neuroinflammation study
Neuroinflammation study by combining human iPSC-derived astrocytes and HTRF.
whitepaper
Whitepaper: iPSC manufacturing for drug discovery
Controlled manufacturing of hiPSC-derived cardiomyocytes in stirred-tank bioreactors enabling high-throughput phenotypic screening.
video
Video: Ncardia’s iPSC technology
This Ncardia company presentation will explain how human stem cell technology offers a solution for drug screening as well as cell therapy projects.
article
The Crick HTS facility – facilitating research through large-scale screening
The high-throughput screening (HTS) facility at the Francis Crick Institute in the UK provides a core service for Crick research groups. It enables scientists to use large-scale, unbiased screening technologies and approaches as part of their research. Nikki Withers spoke to the Science Technology Platform Head, Michael Howell, to hear…
article
High-throughput screening as a method for discovering new drugs
High-throughput screening is a common method of identifying lead compounds for drug development. The most common targets are enzymes – catalytic proteins that perform chemical reactions in the cell. In this article, Matthew Lloyd discusses the opportunities and challenges associated with this approach.
article
If Columbus had a map… guiding the discovery of new drugs
Exploring large databases and selecting compounds of interest can be extremely time-consuming for researchers. Here, Sacha Javor, Horst Flotow and Jingwen Shi discuss a novel chemoinformatics approach for drug discovery.
article
Current state of NAFLD treatments and the promise of in vitro platforms towards better screening of drug candidates
The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.
article
Expert view: Finding a translatable disease model suitable for drug discovery screening
Effective drug discovery and development greatly relies on the availability of predictive pre-clinical models.
article
Screening In-Depth Focus 2020
Included in this in-depth focus are articles on how high-throughput screening can be used to identify lead compounds, using chemoinformatics as a map to guide drug discovery and a novel in vitro model to screen potential treatments for non-alcoholic fatty liver disease (NAFLD).
webinar
Phenotypic screening using iPSC-based human disease biology
18 February 2019 | By Tecan and Ncardia
Ncardia, will discuss the application of human iPSC-derived cell-based assays and high throughput screening for drug discovery and development.
